The interactions of the cells in the bone microenvironment play important roles in bone remodeling. Osteoblasts are involved in the bone remodeling through the production of soluble factors that regulate proliferation and dierentiation of osteoclasts and through cell ± cell interactions. Histological studies have suggested that endothelial cells are also associated with some osteolytic bone diseases. However, it is still unclear how endothelial cells contribute to bone resorption. We established bone-derived endothelial cells (BDECs) to study their roles in bone remodeling. The established BDECs promoted bone resorption in a murine neonatal calvaria organ culture system by secreting a soluble bone resorption-inducing factor(s) when stimulated by several in¯ammatory cytokines. This bone resorptioninducing factor was identi®ed as interleukin-11 (IL-11). IL-11 is known to enhance bone resorption by promoting osteoclastogenesis and by suppressing the activity of osteoblasts. The production of IL-11 in BDECs was also promoted by conditioned medium of human melanoma A375M cells. Because A375M cells formed osteolytic bone metastasis in vivo, BDECs might be involved in pathological osteolysis by producing IL-11. These results suggest that endothelial cells in bone play important roles in the promotion of bone resorption by secreting IL-11 in physiological and pathological conditions.
Introduction
Bone is a dynamic organ that undergoes formation and resorption throughout life. In this bone remodeling, osteoblasts participate in the bone formation, and osteoclasts mediate the bone resorption (Martin and Ng, 1994) . Alterations of the balance between the activities of these cells are believed to play an important role in osteolytic and osteoblastic disorders. Several cytokines and hormones regulate the activities of osteoblasts and osteoclasts (Roodman, 1993) . Interferons (IFNs) suppress bone resorption both by inhibiting the formation and the activity of osteoclasts and by stimulating osteoblast-mediated bone formation (Roodman, 1993) . However, transforming growth factor-b (TGF-b), colony-stimulating factors (CSFs), interleukin-1 (IL-1), tumor necrosis factors (TNFs) and IL-6 stimulate bone resorption by enhancing the formation and the activity of osteoclasts (Tashjian et al., 1985; Oreo et al., 1989; Jilka et al., 1992; Roodman, 1993; Tamura et al., 1993; Morinaga et al., 1997) .
Recent studies have suggested that IL-11 is an important factor that regulates bone remodelling (Tamura et al., 1993; Girasole et al., 1994; Elias et al., 1995; Suda et al., 1995; Morinaga et al., 1997) . IL-11 was originally identi®ed as a cytokine that could induce the proliferation of IL-6-dependent T1165 cells (Paul et al., 1990) . Like IL-6, IL-11 is associated with bone resorption because it induces osteoclastogenesis (Tamura et al., 1993) and suppresses the activity of osteoblasts (Hughes and Howells, 1993) . IL-11 is known to be secreted from osteoblasts and ®broblasts (Suen et al., 1994; Yang and Yang, 1994; Elias et al., 1995; Morinaga et al., 1997) . We previously found that human melanoma A375M cells formed osteolytic bone metastasis in vivo when the cells were injected into the left ventricles of BALB/c nude mice (Morinaga et al., 1997) . Since A375M cells enhanced IL-11 production from the human osteoblast-like cell line Saos-2 (Morinaga et al., 1997) , osteoblasts might participate in the enlargement of bone metastatic foci of A375M cells by producing IL-11.
The histological study of bone metastasis has revealed that most metastatic foci occur near the epiphyseal plate where microvasculatures are abundant (Sasaki et al., 1995) . Some osteolytic bone diseases are also known to be associated with excessive angiogenesis in bone (Dickson et al., 1987 (Dickson et al., , 1990 ). Hence, it is possible that bone endothelial cells participate in the regulation of bone remodeling as osteoblasts. However, it is still unclear how these endothelial cells participate in physiological and pathological bone resorption.
In this study, we established three dierent bonederived endothelial cells (BDECs) from the knee joint, bone marrow, and cortical bone of the femur. We found that when BDECs were treated with several in¯ammatory cytokines and the conditioned medium of A375M cells, they all secreted a bone resorptioninducing factor(s) that promotes calcium release in vitro from neonatal murine calvaria. We identi®ed the bone resorption-inducing factor secreted from BDECs as IL-11. The production of IL-11 was not observed in the mouse brain-derived endothelial cell line MBEC4 and the mouse aortic endothelial cell line MAEC3. These ®ndings indicate that BDECs are speci®cally involved in bone resorption by producing the osteoclast-regulating cytokine IL-11.
Results

Establishment of bone-derived endothelial cells (BDECs)
Since endothelial cells have been implicated in bone resorption (Dickson et al., 1987 (Dickson et al., , 1990 , we tried to isolate endothelial cells of bone origin. Several clones of mouse BDECs were established from the femurs of BALB/c mice after transformation with the SV40 virus. BC-1 and BC-2 were established from the endothelium in cortical bone. BM-1, BM-2 and BM-3 were cloned from the endothelium in bone marrow. KN-1, KN-2 and KN-3 were isolated from the endothelium in trabecular bone near the knee joint. All the established BDECs have polygonal adherent appearances ( Figure  1a) . When the cells were con¯uently cultured, they formed a monolayer with a cobblestone morphology (data not shown).
To con®rm that the established clones possessed the nature of endothelial cells, we examined the capability of BDECs to uptake acetylated low density lipoprotein (acetyl-LDL), a marker of endothelial cells. When BDECs were treated with¯uorescence-labeled acetyl-LDL, all of the clones showed¯uorescent deposits throughout the cytoplasm (Figure 1b) . Mouse macrophages also expressed the receptor for acetyl-LDL (Figure 1d ). To exclude the possibility that the established clones were of macrophage origin, we examined the expression of Mac-1 antigen (CD11b), a macrophage-speci®c marker antigen (Figure 2a ), in these BDECs. None of the isolated clones expressed this antigen (Figure 2c and d) . The antigen was not expressed in mouse lymph node-derived CA-12 stromal cells (Figure 2b) .
We examined the expression of CD34, CD105, and CD106, which are expressed in endothelial cells (Wilkins and Jones, 1995) ; KN-3 cells also expressed these antigens (Figure 3a ± c, respectively). The expression of CD54, CD62e and CD102, which are not generally expressed in non-activated endothelial cells, could hardly be detected in KN-3 cells ( Figure   3d ± f, respectively). We had similar results with BC-1, BM-1 and BM-3 cells (data not shown). All BDECs formed branching vascular structures in a timedependent manner when cultured on a supportive basement membrane gel (Matrigel) (Figure 4 ). These results indicate that all the established clones have natures of endothelial cells.
Regulation of IL-11 expression in BDECs by cytokines and growth factors
To examine whether BDECs were involved in bone remodeling, we examined the eects of the conditioned medium of KN-3 cells (KN-3-CM) on bone resorption using a mouse calvaria organ culture system. The CM obtained from unstimulated KN-3 cells did not promote calcium release from murine calvaria (data not shown). However, the CM of KN-3 cells stimulated by an in¯ammatory cytokine, recombinant human IL-1a (rhIL-1a), strongly promoted bone resorption (data not shown). We, therefore, examined the mRNA expression of some osteoclast-regulating cytokines in BDECs before and after stimulation with IL-1a. When KN-3 and BC-1 cells were stimulated with rhIL-1a for 24 h, both clones were promoted to express IL-11 mRNA (Figure 5a ). The expression level of IL-6 mRNA was also promoted (Figure 5a ). We could not detect the expression of IL-1a, IL-1b, or macrophage-colony stimulating factor (M-CSF) mRNA in KN-3 and BC-1 cells before or after stimulation with IL-1a (Figure 5a ). The freshly prepared normal KN cells also expressed IL-11 and IL-6 mRNA after stimulation with IL-1a ( Figure 5b ).
We further investigated what kinds of agonists could promote IL-11 mRNA expression in KN-3 cells. Addition of phorbol 12-myristate 13-acetate (PMA), rhIL-1a, and hTGF-b 1 increased IL-11 mRNA expression ( Figure 5c , lanes 3, 5 and 6, respectively). However, rhTNF-a had little eect on IL-11 mRNA expression ( Figure 5c , lane 4). Figure 1 DiI-acetyl-LDL uptake in KN-3 cells. KN-3 cells (a and b) and mouse peritoneal macrophages (c and d) were reacted with DiI-acetyl-LDL (10 mg/ml) for 4 h at 378C. After ®xing with 3% formaldehyde in PBS, specimens were viewed with both phase contrast and¯uorescence techniques, as described in Materials and methods. a and c, phase-contrast optics; b and d,¯uorescent optics. Bars, 100 mm In the SV40-transformed mouse brain capillary endothelial MBEC4 and SV40-transformed mouse aortic endothelial MAEC3 cell lines. IL-1a promoted the expression of IL-6 mRNA (Figure 5d and e). However, we could not detect the expression of IL-11 mRNA in either MBEC4 or MAEC3, even after stimulation with IL-1a (Figure 5d and e), indicating the speci®city of BDECs for IL-11 mRNA expression. We reported previously that under physiological conditions IL-6 was not involved in bone resorption Figure 3 Expression of CD34, CD105, CD106, CD54, CD62e, and CD102 in BDECs. KN-3 cells were reacted with FITCconjugated or unconjugated anti-mouse CD34 (a), CD105 (b), CD106 (c), CD54 (d), CD62e (e) and CD102 (f) (bold lines) or normal IgG (dotted lines). In some experiments, cells were further treated with FITC-conjugated appropriate second antibodies. After washing with PBS, the¯uorescence intensity of the cells was analysed using FACScan, as described in Materials and methods Figure 4 Morphological examination of the KN-3 cells cultured on Matrigel. KN-3 cells were harvested and cultured on Matrigelcoated wells for 2 h (a), 1 day (b), 2 days (c), 3 days (d), 4 days (e), and 7 days (f). The specimens were viewed using phase contrast optics, as described in Materials and methods
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To con®rm these results, we measured the change of IL-11 protein concentration in KN-3-CM through bioassay of MH60 cells, because ELISA kits for detecting mouse IL-11 protein amount were not commercially available. As the growth of MH60 cells was dependent on IL-6 and IL-11 (Figure 6a , solid columns), we determined the IL-11 bioactivity by adding a sucient amount of anti-IL-6 monoclonal antibody (mAb) to neutralize the growth-promoting activity of IL-6 and by comparing a standard curve set up with known amounts of human IL-11. The anti- (7) or the presence (+) of 2.5 ng/ml rhIL-1a. mRNA was extracted, and RT ± PCR was performed using primer sets of mG3PDH, mIL-1a, mIL-1b, mIL-6, mIL-11 or mM-CSF. The ampli®ed products, mG3PDH (983 bp), mIL-1a (491 bp), mIL-1b (563 bp), mIL-6 (638 bp), mIL-11 (462 bp) or mM-CSF (568 bp), were electrophoresed on a 1.8% agarose gel plate and visualized by U.V. illumination following ethidium bromide staining. The molecular size marker was the 100 bp DNA ladder (lane M). Repeated experiments gave similar results. (b) Freshly prepared normal KN cells were incubated for 24 h in the absence (7) or the presence (+) of 2.5 ng/ml rhIL-1a. mRNA was extracted, and RT ± PCR was performed using primer sets of mG3PDH, mIL-1a, mIL-6, mIL-11 or mM-CSF. The ampli®ed products, mG3PDH (983 pb), mIL-1a (491 bp), mIL-6 (638 bp), mIL-11 (462 bp) or mM-CSF (568 bp), were electrophoresed on a 1.8% agarose gel plate and visualized by U.V. illumination following ethidium bromide staining. The molecular size marker was the 100 bp DNA ladder (lane M). The contamination of the CD105-negative non-endothelial cells in the used KN cell fraction was about 10% by analysis on FACS (data not shown). Repeated experiments gave similar results. (c) KN-3 cells were incubated for 24 h with medium alone (lane 2) or medium containing 50 ng/ml PMA (lane 3), 10 ng/ml rhTNF-a (lane 4), 2.5 ng/ml rhIL-1a (lane 5) and 10 ng/ml hTGF-b 1 (lane 6). mRNA of each sample was extracted, and RT ± PCR was carried out using mIL-11 and mG3PDH primer sets. PCR was also carried out without cDNA (lane 1). The ampli®ed products were electrophoresed on a 1.8% agarose gel plate and visualized by U.V. illumination following ethidium bromide staining. Repeated experiments gave similar results. (d, e) MBEC4 (d) and MAEC3 (e) cells were incubated for 24 h in the absence (7) or the presence (+) of 2.5 ng/ml rhIL-1a.
mRNA of each sample was extracted and RT ± PCR was carried out using mG3PDH, mIL-11, and mIL-6 primer sets. The ampli®ed product, mG3PDH (983 bp), mIL-11 (462 bp) or mIL-6 (638 bp), were electrophoresed on a 1.8% agarose gel plate and visualized by U.V. illumination following ethidium bromide staining. The molecular size marker was the 100 bp DNA ladder (lane M). Repeated experiments gave similar results
Figure 6
Production of IL-11 protein in KN-3 cells. (a) MH60 cells were cultured with medium alone (control) or medium containing 10 ng/ml of rmIL-6 or mIL-11 for 48 h (solid columns). Speci®city of neutralizing antibodies was investigated by adding 20 mg/ml of anti-mIL-6 mAb (hatched columns) or 40 mg/ml of anti-mIL-11 mAb (open columns) to the assay medium 1 h before MH60 cells were added (20 mg/ml of antimIL-6 mAb were able to neutralize 10 ng/ml of rmIL-6 bioactivity and 40 mg/ml of anti-mIL-11 mAb could neutralize 10 ng/ml of mIL-11 bioactivity). The growth of MH60 cells was estimated by using the MTT method, as described in After a 24 h culture, IL-11 bioactivity in the KN-3-CM was estimated by the growth of MH60 cells in the presence of 20 mg/ ml of anti-mIL-6 mAb to neutralize the eect of mIL-6 on MH60 cell growth. In some experiments, the neutralizing anti-mIL-11 mAb (40 mg/ml) was added to the assay medium. IL-11 bioactivities in the supernatants were determined from a standard curve set up with known amounts of rhIL-11. Each point represents a mean+s.d. of triplicate determinations mIL-11 mAb and anti-mIL-6 mAb used in this study could speci®cally neutralize the activity of mIL-11 and mIL-6, respectively ( Figure 6a , open and hatched columns, respectively). PMA, rhIL-1a, and hTGF-b 1 enhanced IL-11 production in KN-3 cells in a dosedependent manner ( Figure 6b , hatched, open, and solid columns, respectively), that was consistent with the level of IL-11 mRNA expression ( Figure 5c ). However, rhTNF-a had only a marginal eect on IL-11 production from KN-3 cells ( Figure 6b , dotted columns). We obtained similar results with BC-1 cells (data not shown). These results suggest that endothelial cells in bone may aect bone remodeling by secreting IL-11 when the cells are stimulated by several in¯ammatory cytokines and growth factors.
Enhancement of IL-11 production from BDECs by the CM of cancer cells
To investigate whether BDECs are associated with pathological bone resorption, we examined the eects of human melanoma A375M cells on the production of bone resorption-inducing factors from BDECs because A375M cells formed osteolytic bone metastasis in vivo when the tumor cells were injected into the left ventricles of BALB/c nude mice (Morinaga et al., 1997) . Histological examination revealed that the CM of KN-3 cells alone did not promote bone resorption in neonatal mouse calvaria (Figure 7a ). However, the CM of KN-3 cells that were cultured for 24 h with 50% of the A375M-CM increased the number of tartrate-resistant acid phosphatase (TRAPase)-positive multinucleared osteoclasts (Figure 7b , arrows) and promoted the loss of calvarial bone matrix ( Figure 7b ). The CM of A375M cells alone had little eect on the increase of osteoclasts (data not shown) (Morinaga et al., 1997) . Therefore, A375M cells stimulated bone resorption by enhancing the production of a bone resorption-inducing factor(s) from BDECs. To identify these factor(s) secreted by KN-3 cells, we examined the change of mRNA expression of some osteoclast-regulating cytokines when KN-3 cells were stimulated with A375M-CM. As shown in Figure 8a , the addition of A375M-CM promoted the IL-6 and IL-11 mRNA expression. The mRNA expressions of other cytokines and growth factors were not changed by A375M-CM. IL-6 and IL-11 protein expressions were examined by the proliferative response of MH60 cells to KN-3-CM. The growth of MH60 cells was stimulated by the CM of KN-3 cells that had been stimulated by A375M-CM, in a dose-dependent fashion (Figure 8b , open circles). Since the growthpromoting eects of KN-3-CM were diminished by the neutralizing eect of anti-mIL-6 mAb ( Figure 8b , open squares) or the combination of the neutralizing eects of anti-mIL-6 and anti-mIL-11 mAbs (Figure 8b , open triangles), A375M-CM enhanced both IL-6 and IL-11 protein expression from KN-3 cells.
The CM of KN-3 cells, which had been stimulated by A375M-CM, promoted bone resorption of neonatal mouse calvaria (Figure 7b ). Under these conditions, the calcium concentration in the organ culture medium, resulting from bone resorption of calvaria, was signi®cantly increased (Figure 9 ). However, unstimulated KN-3-CM or A375M-CM alone had marginal eect. Since the increase in the calcium concentration of organ culture medium was suppressed by the antimIL-11 mAb ( Figure 9 , open columns), but not by the anti-mIL-6 mAb ( Figure 9 , hatched columns), A375M cells promoted bone-resorption by enhancing IL-11 production from BDECs through secreting some factors.
Involvement of IL-1a in the A375M-induced IL-11 production in BDECs
Because metastatic A375M cells stimulated bone resorption in the neonatal mouse calvaria organ culture system by enhancing IL-11 production in KN-3 cells (Figure 9 ), we tried to identify the responsible factor(s) contained in A375M-CM. The mRNA expression of several cytokines and growth factors in A375M cells was assessed using the reverse transcription-polymerase chain reaction (RT ± PCR) method. A375M cells expressed IL-1a and TGF-b 1 mRNA ( Figure 10a , lanes 2 and 5, respectively). However, the mRNA expression of IL-1b, TNF-a, TNF-b and TGF-b 2 could not be detected (Figure 10a , lanes 3, 4, 6 and 7, respectively) (Morinaga et al., 1997) . As both IL-1a and TGF-b 1 promoted the expression of IL-11 mRNA and protein in KN-3 cells Figure 7 Increase in the number of osteoclasts by the CM of KN-3 cells precultured with CM from bone metastatic human melanoma A375M cells. KN-3 cells were cultured in the absence (a) or the presence (b) of 50% of the A375M-CM. After a 24 h culture, the CM of KN-3 cells was collected. Neonatal murine calvaria were then incubated with 50% of the CM for 7 days. At the end of the culture period, the multinucleared osteoclasts (indicated by arrows) were stained with TRAPase and hematoxylin, as described in Materials and methods. Bars, 100 mm (Figure 5c and 6b, respectively), we attempted to determine whether IL-1a or TGF-b 1 was mainly associated with the IL-11 production using the neutralizing anti-hIL-1a polyclonal antibody (pAb) and anti-hTGF-b mAb. As shown in Figure 10b , the eects of A375M-CM on IL-11 production from KN-3 cells was neutralized when anti-hIL-1a pAb was added but not anti-hTGF-b mAb. These results indicate that IL-1a is the main factor involved in A375M-induced IL-11 production in BDECs.
To con®rm these results, we measured TGF-b 1 concentrations using a speci®c enzyme-linked immunosorbent assay (ELISA) kit (Table 1) . We could not detect the presence of an active or a latent form of TGF-b 1 protein in A375M-CM. When we examined the concentrations of IL-1a, we found that A375M cells de®nitely produced IL-1a protein (0.58 ng/ml) ( Table 1) . These results indicate that IL-1a is the factor associated with A375M-induced IL-11 production from BDECs.
Discussion
Endothelial cells are members of a complex regulation network in bone and are believed to regulate bone physiological functions by producing soluble factors or by mediating cell ± cell adhesion (Zaidi et al., 1993; Collin-Osdoby, 1994; Formigli et al., 1995) . Several investigators have suggested that endothelial cells contribute to both bone-formative and bone-resorptive processes (Guenther et al., 1986; Villanueva and Nimni, 1990; Alam et al., 1992; Zaidi et al., 1993; Collin-Osdoby, 1994) . Histological studies have underscored the importance of endothelial cells in bone remodeling (Jae, 1930; Trueta, 1963; Soskolne, 1979; Dickson et al., 1987 Dickson et al., , 1990 . In regard to the soluble factors, endothelial cells are known to produce many mediators (e.g., IL-1, IL-6, FGFs, CSFs and nitric oxide) either constitutively or in response to stimuli (Zaidi et al., 1993; Collin-Osdoby, 1994) . These factors have also been reported to modulate the activities of osteoblasts and osteoclasts (Roodman, 1993) . Therefore, endothelial cells in bone might be involved in bone development, remodeling, and some osteolytic and osteoblastic bone diseases. However, it is still unclear how endothelial cells in bone regulate bone remodeling.
We here established BDECs from femurs of BALB/c mice by transformation of SV40 virus to identify the molecules involved in bone remodeling. All the established BDECs expressed the receptor for acetyl-LDL (Figure 1 ) but did not express the Mac-1 antigen (CD11b) (Figure 2) . The BDECs also expressed CD34, 
mg/dl). Data represent means+s.d. of triplicate determinations
The role of IL-11 in osteolytic bone metastasis Y Zhang et al CD105 and CD106, which were known to be expressed in endothelium (Figure 3a ± c, respectively) (Wilkins and Jones, 1995). Moreover, BDECs formed vascular structures when cultured on Matrigel-coated dishes (Figure 4 ). Electron microscopic analysis revealed that BDECs were attached to each other with desmosomelike junctional complexes (data not shown). Therefore, we concluded that the established clones were of bone endothelial origin. Although non-activated BDECs-CM did not promote bone resorption in the neonatal mouse calvaria organ culture system (Figures 7a and 9) , the CM of BDECs, stimulated by IL-1a contained in A375M-CM, strongly promoted bone resorption (Figure 7b ). IL-11 was identi®ed as the bone resorption-inducing factor secreted by BDECs in response to IL-1a (Figure 5a and  b) . The expression of IL-11 mRNA in KN-3 and BC-1 cells was also promoted by PMA and TGF-b 1 but not by TNF-a (Figures 5c and 6 ). As the mRNA expression of other soluble factors (e.g., IL-1a, IL-1b and M-CSF) could not be detected (Figure 5a and b), IL-11 was the soluble factor involved in BDECmediated bone resorption. We could not detect the expression of IL-11 mRNA in the mouse brain capillary-derived endothelial cell line MBEC4 and in the mouse aortic endothelial cell line MAEC3, even when they were stimulated by IL-1a (Figure 5d and e, respectively). As both MBEC4 and MAEC3 were established by transformation with SV40 virus (Tatsuta et al., 1992) , IL-11 expression in KN-3 and BC-1 cells might not be the result of SV40 transformation. Furthermore, freshly prepared non-transformed KN cells expressed IL-11 mRNA after stimulation with IL-1a (Figure 5b) . Therefore, the endothelial cell in bone was distinguished from endothelial cell in other tissues by such characteristics as the production of IL-11.
IL-11 had various biological functions, such as an inducing acute-phase protein, a thrombopoietic factor, a competence factor for hematopoietic stem cells, and an antibody secretion (Girasole et al., 1994) . IL-11 could induce osteoclast formation in vitro (Tamura et al., 1993) and inhibit calci®cation of osteoblasts (Hughes and Howells, 1993) . Since neutralization of IL-11 suppressed osteoclast development induced by 1,25(OH) 2 D 3 , PTH, IL-1 or TNF (Girasole et al., 1994; Manolagas, 1995) , IL-11 plays an important role in the regulation of bone remodeling.
IL-6 possesses biological functions similar to IL-11 and shares the common b subunit receptor, gp130, in signal transduction (Kishimoto et al., 1994) . However, unlike IL-11, IL-6 itself cannot promote osteoclast formation in vitro under physiological conditions. A soluble IL-6 receptor is indispensable for IL-6 to exhibit osteoclastogenesis (Tamura et al., 1993) . In another experiment, IL-11 was associated with the osteoclastogenesis in ovariectomized mice in the same way as was in sham-operated mice (Girasole et al., 1994) . IL-6 seemed to be involved in osteoclast formation only in pathological states (i.e., without estrogen) because the neutralizing antibody to IL-6 inhibited the increase of osteoclasts in ovariectomized mice but not in sham-operated mice in vivo (Jilka et al., 1992) . All of the above observations indicate that IL-11 plays an important role in osteoclast formation in general. Although the expression of IL-6 was also stimulated by several in¯ammatory cytokines in A375M-CM was also incubated without antibodies for 2 h (solid columns). Speci®city of neutralizing antibodies was investigated by adding them to the medium containing 2.5 ng/ml of rhIL-1a or 1 ng/ml of hTGF-b 1 (40 mg/ml of anti-hIL-1a pAb were able to neutralize 4 ng/ml of hIL-1a bioactivity and 40 mg/ml of hTGF-b 1 mAb were able to neutralize 2 ng/ml of hTGF-b 1 bioactivity). Then KN-3 cells were incubated for 24 h with A375M-CM or medium containing rhIL-1a or hTGF-b 1 . IL-11 bioactivity in the KN-3-CM was estimated by the growth of MH60 cells using MTT method in the presence of 20 mg/ml of neutralizing antimIL-6 mAb to exclude the eect of mIL-6 on MH60 cell growth Human melanoma A375M, breast cancer MDA-MB-231, lung cancer A549, and prostate cancer PC3 cells were precultured with serum-free medium at 378C for 4 h. Then medium was replaced with fresh serum-free medium and the culture continued for another 48 h. The conditioned media of the tumor cells were ®ltrated and stored at 7208C until use. The concentrations of TGF-b 1 and IL-1a in the CM (150 mg protein/ml) were determined using commercially available ELISA kits, as described in Materials and methods. Detection limit of TGF-b 1 or IL-1a was a 0.05 ng/ml or b 0.20 ng/ml
The role of IL-11 in osteolytic bone metastasis Y Zhang et al BDECs (Figure 5a and b), it had no eect on bone resorption in our calvaria organ culture system ( Figure  9 ) (Morinaga et al., 1997) . Therefore, regulation of bone resorption by BDECs was due to the production of IL-11, but not of IL-6. To determine whether BDECs were associated with diseases such as a osteolytic bone metastasis, we investigated the eects of bone metastatic A375M human melanoma cells on the production of a bone resorption-inducing factor from BDECs. We found that the CM of A375M cells stimulated IL-11 production from KN-3 cells (Figure 8) . Because the addition of anti-mIL-11 mAb could neutralize A375M-mediated bone resorption in mouse calvaria organ culture system (Figure 9 ), the induction of IL-11 production from BDECs was indispensable for A375M-mediated bone resorption. These results indicate that BDECs are involved in the progression of bone resorption at the bone metastatic foci of A375M cells by producing IL-11.
A375M cells constitutively expressed IL-1a and TGF-b1 mRNA (Figure 10a ). However, active or latent forms of TGF-b 1 could not be detected in A375M-CM (Table 1) . As an anti-IL-1a pAb could almost completely neutralize A375M-induced IL-11 production in KN-3 cells (Figure 10b ), the production of IL-1a in cancer cells might facilitate the enlargement of metastatic foci in bone through the formation and activation of osteoclasts by enhancing IL-11 production in BDECs. Since IL-1 caused hypercalcemia by increasing the numbers of osteoclasts in vivo (Sabatini et al., 1988) and neutralization of IL-11 suppressed the IL-1-induced osteoclast development (Girasole et al., 1994; Manolagas, 1995) , BDECs might also be involved in such IL-1-mediated pathological bone resorption by producing IL-11.
Breast and lung tumor cells preferentially metastasized to bone and formed osteolytic bone metastasis (Yoneda et al., 1994) . When we examined the production of IL-1a and TGF-b 1 , we found that human breast cancer MDA-MB-231 cells and human lung cancer A549 cells produced both factors to some extent (Table 1) . MDA-MB-231 cells were also known to produce IL-11 by themselves (Morinaga et al., 1997) . As both IL-1a and TGF-b 1 promoted IL-11 production by BDECs (Figures 5c and 6b) , the production of either factor might facilitate the formation of osteolytic bone metastasis. In contrast to breast and lung tumor cells, prostate cancer cells often formed osteoblastic bone metastasis (Burki et al., 1987) . Human prostate PC3 cells, that formed osteoblastic bone metastasis in vivo (Perkel et al., 1990) , produced neither IL-1a nor TGF-b 1 (Table 1) . This result also suggested a relationship between the ability to form osteolytic bone metastasis of cancer cells and the production of either IL-1a or TGF-b 1 .
IL-11 was known to stimulate the osteoclast dierentiation (Tamura et al., 1993) . However, the dierentiated osteoclast cell number may not simply re¯ect the bone resorptive ability. The dierentiated osteoclasts need another step to exert the bone resorptive ability. We have reported herein that IL-11 increases osteoclast cell number (Figure 7 ) and stimulates bone resorption in vitro (Figures 6a and 9) . The possibility of IL-11 to enhance the bone-resorptive activities of osteoclast, in addition to the promotion of the dierentiation of osteoclasts, needs to be examined in future. However, it is not known whether IL-11 directly aects osteoclasts. Because IL-11 could not promote osteoclastogenesis from bone marrow cells in the absence of calvaria cells (Girasole et al., 1994) , it might indirectly promote dierentiation and activation of osteoclasts through activating calvaria cells. Recent studies have revealed that the IL-11 receptor is composed of a speci®city-determining a chain (IL11Ra) and of gp130 (Yin et al., 1993; Hilton et al., 1994; CheÂ rel et al., 1995) . IL-11 binds ®rst to its speci®c low-anity IL-11Ra and then to two subunits of gp130 to generate a high-anity complex (Bellido et al., 1996) . Mouse osteoblasts and human osteoblastlike Saos-2 and Mg-63 cells expressed the IL-11 receptor a chain (CheÂ rel et al., 1995; Bellido et al., 1996; Romas et al., 1996) . We also found that BDECs expressed the murine IL-11 receptor a chain and gp130 (unpublished data). Therefore, IL-11 might stimulate BDECs and osteoblasts to secrete soluble factors that directly aect osteoclasts in autocrine and paracrine ways. Identi®cation of such factors may contribute to the development of a new treatment of osteolytic bone diseases.
Materials and methods
Chemicals and reagents
Cytokines used in this study were rhIL-1a (R&D Systems, Minneapolis, MN), rhIL-11 (Boehringer Mannheim, Mannheim, Germany), rhTNF-a (Genzyme Corp., Cambridge, MA), natural hTGF-b 1 (Genzyme), and recombinant mouse IL-6 (rmIL-6; Boehringer Mannheim). Mouse IL-11 (mIL-11) was produced by transfecting the fulllength cDNA of mIL-11 (kindly given by Genetics Institute, Cambridge, MA) into COS-7 cells.
Brie¯y, a NotI ± NotI fragment of mIL-11 cDNA (Morris et al., 1996) was cloned into the NotI site of the pOPSRa vector (Yamada et al., 1997) to generate pOPSRa-mIL-11. Ten micrograms of pOPSRa-mIL-11 was transiently transfected into COS-7 cells. After transfection, COS-7 cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM; Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 2 mM L-glutamine (Gibco Laboratories, Grand Island, NY), 100 mg/ml kanamycin (Meiji Seika Co. Ltd., Tokyo, Japan) and 10% heat-inactivated FBS (Gibco) (DMEM growth medium) for 6 days at 378C in a humidi®ed atmosphere of 95% air and 5% CO 2 . The CM containing mIL-11 was ®ltrated and stored at 7208C until use. The bioactivity of mIL-11 in the CM was determined by comparing the known amount of rhIL-11, as described below. Untransfected COS-7 cells did not spontaneously secrete IL-6 nor IL-11 (data not shown).
The neutralizing antibodies used in this study were rabbit anti-hIL-1a pAb (10 mg/ml of antibody could neutralize 1 ng/ ml of rhIL-1a bioactivity; Endogen, Inc., Boston, MA), murine anti-hTGF-b mAb (20 mg/ml of antibody could neutralize 1 ng/ml of TGF-b bioactivity; Genzyme), rat anti-mIL-6 mAb (2 mg/ml of antibody could neutralize 1 ng/ml of rmIL-6 bioactivity; Boehringer Mannheim) and murine anti-mIL-11 mAb (4 mg/ml of antibody could neutralize 1 ng/ml of mIL-11 bioactivity; a generous gift of Steven Clark, Ph.D., Genetics Institute). PMA were purchased from Sigma (St Louis, MO).
Isolation of mouse BDECs
Endothelial cells were isolated according to the method described previously (Tatsuta et al., 1992) . Brie¯y, femurs
The role of IL-11 in osteolytic bone metastasis Y Zhang et al of BALB/c mice (Charles River Japan Inc., Kanagawa, Japan) were isolated and washed with phosphate-buered saline (PBS). After removing the smooth muscle and periosteum, bone marrow (BM) cells were collected. The remaining bone was cut into pieces and treated with 0.5% collagenase in Hanks' balanced salt solution, without calcium and magnesium, for 15 min at 378C, with gentle shaking. The removed cells (BC cells) were collected and cultured. The knee joint was cut into pieces and treated with collagenase. The removed cells (KN cells) were collected and cultured. All of these cells were resuspended in DMEM growth medium containing 598 mg/ml D-valine (Sigma) to suppress the growth of ®broblasts. The cells were then seeded into gelatin-coated dishes. After cultivation for 2 weeks, the adherent cells were treated with 1.5610 8 p.f.u. of SV40 virus (strain 777) for 2 h as described previously to establish mouse brain capillary endothelial cell lines (Tatsuta et al., 1992) . Then BDECs were cultured in medium containing D-valine in 96-well plates, and several clones were isolated. The cloned BDECs were maintained in DMEM growth medium without Dvaline on gelatin-coated dishes.
Acetyl-LDL uptake in BDECs
To con®rm that the BDECs were of endothelial origin, they were washed with serum-free DMEM and then incubated with 1,1'-dioctadecyl -3, 3, 3',3',-tetramethylindocarbocyanine perchlorate-labeled acetyl-LDL (DiI-acetyl-LDL; Biomedical Technologies, Stoughton, MA) at 20 mg/ml for 4 h in a Labtech chamber (Nunc, Roskilde, Denmark) (Tatsuta et al., 1992) . After washing and ®xing with 3% formaldehyde in PBS, specimens were viewed through a microscope using both phase contrast and¯uorescence techniques (Nikon OPTIPHOT, Tokyo, Japan).
Flow cytometric analysis of the antigen expressed in BDECs
To con®rm that the BDECs were not macrophages, they and peritoneal macrophages were treated with rat antimouse Mac-1 (CD11b) mAb (Chemicon, Temecula, CA) or with control normal rat IgG (Zymed, San Francisco, CA) for 30 min at 48C. Then the cells were washed with PBS and treated with FITC-conjugated anti-rat IgG (Cappel, Cochranville, PA). Fluorescence data were collected using a Becton Dickinson FACScan (San Jose, CA), as described previously (Noguchi et al., 1996) . The expression of CD34, CD54 (intercellular adhesion molecule-1, ICAM-1), CD62e (endothelial leukocyte adhesion molecule-1, ELAM-1), CD102 (ICAM-2), CD105 (endoglin), and CD106 (vascular cell adhesion molecule-1, VCAM-1) in freshly prepared KN cells and cloned BDECs were also examined using anti-CD34 mAb (Pharmingen, San Diego, CA), FITC-conjugated anti-CD54 mAb (Pharmingen), antiCD62e mAb (Pharmingen), FITC-conjugated anti-CD102 mAb (Pharmingen), anti-CD105 mAb (Pharmingen), or FITC-conjugated anti-CD106 mAb (Pharmingen) for 30 min at 48C. In control experiments, BDECs were reacted with appropriate FITC-conjugated or unlabeled control IgG (Zymed, Rockland, Gilbertsville, PA; or Cedar Lane, Ontario, Canada). In some experiments, cells were further treated with appropriate FITC-conjugated anti-rat IgG (Rockland). Fluorescence data were collected using a FACScan.
Morphological examination of BDECs cultured on matrigel
Matrigel (Becton Dickinson, Bedford, MA) was diluted with cold PBS and applied to 24-well plates. BDECs were cultured on the wells in DMEM growth medium over 7 days. The specimens were viewed with phase contrast optics using a microscope (Nikon).
Other cell lines and culture conditions
The SV40-transformed mouse brain capillary endothelial cell line MBEC4 and the SV40-transformed mouse aortic endothelial cell line MAEC3 were established in our laboratory, as described previously (Tatsuta et al., 1992) . The A375M human melanoma cell line is a variant of the A375 parental line and has a high metastatic potential (Hendrix et al., 1990) . The human breast cancer cell line MDA-MB-231 and the human lung tumor cell line A549 were obtained from American Tissue Culture Collections (Giard et al., 1973; Cailleau et al., 1974) . The human prostate cancer cell line PC3 (Ohnuki et al., 1980) was obtained from Japanese Cancer Cell Resources Bank (JCRB, Saitama, Japan). MBEC4, MAEC3, A375M, MDA-MB-231, A549 and PC3 cells were cultured in DMEM growth medium (Morinaga et al., 1997) . The mouse lymph node stromal cell line CA-12 (Fujita et al., 1993) was used as a control and was cultured in RPMI 1640 (Nissui) supplemented with L-glutamine, kanamycin, and 10% heat-inactivated FBS (RPMI growth medium).
Preparation of the conditioned medium
To obtain the CM of A375M, MDA-MB-231, A549, PC3 cells, cancer cells (1610 5 cells/ml) were grown in 10 ml DMEM growth medium to subcon¯uence. Then the cells were washed twice with PBS and cultured in fresh serumfree DMEM. After a 4 h culture, medium was replaced with 10 ml fresh serum-free medium and the cell culture continued for an additional 48 h. The CM was ®ltrated and stored at 7208C until needed. To obtain the CM of BDECs and other cells, the subcon¯uent cells were precultured for 24 h in serum-free medium containing 0.1% BSA. After washing with PBS, medium was replaced with fresh serum-free medium containing 0.1% BSA and the above-mentioned cytokines or the A375M-CM. After cultivation for another 24 h, the CM was ®ltrated and stored at 7208C until the concentrations of IL-11 and IL-6 were measured, as described below. At the end of cell culture, mRNA of the cells was extracted.
IL-11 bioassays
IL-11 bioactivity in the CM was determined by measuring the proliferative response of the IL-6-and IL-11-dependent MH60 cell line (generously provided by Ajinomoto Co., Inc.) (Matsuda et al., 1988) . MH60 cells were maintained in RPMI growth medium supplemented with 1 ng/ml of rhIL-11. When determining the concentrations of IL-11 in the CM, MH60 cells were cultured for 48 h with or without the CM in the presence of 20 mg/ml of anti-mIL-6 mAb to neutralize the eects of IL-6 (this concentration of mAb was sucient to block 10 ng/ml of rmIL-6 bioactivity in this bioassay). The proliferative response of the cells was measured using the MTT method, as described previously (Morinaga et al., 1997) . In some experiments, the CM was preincubated with neutralizing anti-mIL-11 mAb for 1 h at 378C before MH60 cells were added. IL-11 concentrations in the supernatants were determined from a standard curve set up with known amounts of rhIL-11.
Reverse transcription-polymerase chain reaction (RT ± PCR) mRNA was extracted using a QuickPrep mRNA isolation kit according to the manufacturer's instruction (Pharmacia, Uppsala, Sweden). RT ± PCR was carried out using a GeneAmp RNA PCR core kit (Perkin-Elmer, Norwalk, CT). Brie¯y, 1 mg of mRNA was reverse transcribed, and one-twentieth of this was then ampli®ed by PCR for 30 cycles (annealing for 45 s at 608C, elongation for 2 min at 728C, and denaturation for 45 s at 948C) using a thermal cycler (PCR System 9600, Perkin-Elmer). The sense and antisense primers of mIL-1a, mIL-1b, mIL-6, mM-CSF, mG3PDH, hIL-1a, hIL-1b, hTNF-a, hTNF-b, hTGF-b 1 , hTGF-b 2 and hG3PDH, were purchased from Clontech Laboratories, Inc. (Palo Alto, CA). mTGF-b 1 sense and antisense primers were purchased from Stratagene (La Jolla, CA). mIL-11 sense (5'-CCTGCTGTTGTTAAA-GACTCGACTGTGA-3') and antisense (5'-TGGCCTC-GAACTCAGAAATCTGC-3') primers were synthesized according to the sequence from Genbank (accession no. U03421) (Paul et al., 1990) . The ampli®ed fragments were detected in the expected sizes by ethidium bromide staining in a 1.8% agarose gel (Lee et al., 1996) .
Determination of IL-1a and TGF-b 1 concentrations by ELISA
The concentrations of hIL-1a and hTGF-b 1 (including latent TGF-b 1 by acid activation) in the CM were quanti®ed using commercially available ELISA kits according to the manufacturers' instructions (Chemicon; Genzyme). The concentrations of hIL-1a and hTGF-b 1 were normalized by determining the total protein amount in the CM using BCA protein assay kit (Bio-Rad, Richmond, CA).
Bone resorption assay
The bone resorption assay was carried out according to a previously described method (Ohishi et al., 1995) . Brie¯y, the calvaria obtained from 3-day-old ICR mice (Charles River, Japan) was divided into hemicalvarial parietal bones, each explant used for an assay. During the assay, the explants were precultured individually for 24 h in serum-free DMEM containing 0.1% BSA and 4.5 g/l of glucose at 378C. Then they were cultured for 7 days with fresh medium, medium containing cytokines or CM from tumors and BDECs. At the end of the culture period, bone resorption was quanti®ed by determining the calcium concentration in the culture supernatant using the Calcium Test Wako (Wako Pure Chemical Industries Ltd., Osaka, Japan) (Ohishi et al., 1995) . The cultured calvaria was stained with TRAPase (a histochemical marker of osteoclasts) and hematoxylin using an acid phosphatase, leukocyte kit (Sigma).
